ReShape Lifesciences Gets FDA Approval for PMA Supplement Used in Latest Lap-Band
Provided by
Dow Jones
By Denny Jacob
ReShape Lifesciences received approval for a PMA supplement for its Lap-Band 2.0 FLEX from the Food and Drug Administration.
The approval is expected to be a growth catalyst for the weight loss and metabolic health solutions company's Lap-Band franchise, said Chief Executive Paul Hickey. He added that the company is preparing for its U.S. product launch of the latest iteration of the Lap-Band.
The FDA-approved Lap-Band System provides minimally invasive, long-term treatment of obesity, said ReShape.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 12, 2023 16:30 ET (21:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits